345 related articles for article (PubMed ID: 30949454)
1. Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine.
Ährlund-Richter A; Cheng L; Hu YOO; Svensson M; Pennhag AAL; Ursu RG; Haeggblom L; Grün N; Ramqvist T; Engstrand L; Dalianis T; Du J
Front Cell Infect Microbiol; 2019; 9():59. PubMed ID: 30949454
[No Abstract] [Full Text] [Related]
2. Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: a review based on our findings 2008-2018, and perspectives on cancer prevention.
Du J; Ährlund-Richter A; Näsman A; Dalianis T
Arch Gynecol Obstet; 2021 Feb; 303(2):329-335. PubMed ID: 33247317
[TBL] [Abstract][Full Text] [Related]
3. Decline of HPV infections in Scandinavian cervical screening populations after introduction of HPV vaccination programs.
Dillner J; Nygård M; Munk C; Hortlund M; Hansen BT; Lagheden C; Liaw KL; Kjaer SK
Vaccine; 2018 Jun; 36(26):3820-3829. PubMed ID: 29778519
[TBL] [Abstract][Full Text] [Related]
4. Pre-vaccination prevalence of human papillomavirus types in the genital tract of 15-23-year-old women attending a youth health clinic in Stockholm, Sweden.
Ramqvist T; Du J; Lundén M; Ahrlund-Richter S; Ferreira J; Marions L; Sparén P; Andersson S; Dalianis T
Scand J Infect Dis; 2011 Feb; 43(2):115-21. PubMed ID: 20964488
[TBL] [Abstract][Full Text] [Related]
5. Monitoring vaccine and non-vaccine HPV type prevalence in the post-vaccination era in women living in the Basilicata region, Italy.
Carozzi F; Puliti D; Ocello C; Anastasio PS; Moliterni EA; Perinetti E; Serradell L; Burroni E; Confortini M; Mantellini P; Zappa M; Dominiak-Felden G
BMC Infect Dis; 2018 Jan; 18(1):38. PubMed ID: 29334901
[TBL] [Abstract][Full Text] [Related]
6. Quadrivalent vaccine-targeted human papillomavirus genotypes in heterosexual men after the Australian female human papillomavirus vaccination programme: a retrospective observational study.
Chow EPF; Machalek DA; Tabrizi SN; Danielewski JA; Fehler G; Bradshaw CS; Garland SM; Chen MY; Fairley CK
Lancet Infect Dis; 2017 Jan; 17(1):68-77. PubMed ID: 27282422
[TBL] [Abstract][Full Text] [Related]
7. Impact of HPV vaccination with Gardasil® in Switzerland.
Jacot-Guillarmod M; Pasquier J; Greub G; Bongiovanni M; Achtari C; Sahli R
BMC Infect Dis; 2017 Dec; 17(1):790. PubMed ID: 29273004
[TBL] [Abstract][Full Text] [Related]
8. Oral human papillomavirus (HPV) prevalence in youth and cervical HPV prevalence in women attending a youth clinic in Sweden, a follow up-study 2013-2014 after gradual introduction of public HPV vaccination.
Grün N; Ährlund-Richter A; Franzén J; Mirzaie L; Marions L; Ramqvist T; Dalianis T
Infect Dis (Lond); 2015 Jan; 47(1):57-61. PubMed ID: 25378085
[TBL] [Abstract][Full Text] [Related]
9. Vaccine and Non-Vaccine HPV Types Presence in Adolescents with Vertically Acquired HIV Five Years Post Gardasil Quadrivalent Vaccination: The ZIMGARD Cohort.
Murahwa AT; Mudzviti T; Mandishora RSD; Chatindo T; Chanetsa P; Pascoe M; Shamu T; Basera W; Luethy R; Williamson AL
Viruses; 2024 Jan; 16(1):. PubMed ID: 38275972
[TBL] [Abstract][Full Text] [Related]
10. Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study.
Basu P; Malvi SG; Joshi S; Bhatla N; Muwonge R; Lucas E; Verma Y; Esmy PO; Poli URR; Shah A; Zomawia E; Pimple S; Jayant K; Hingmire S; Chiwate A; Divate U; Vashist S; Mishra G; Jadhav R; Siddiqi M; Sankaran S; Prabhu PR; Kannan TPRA; Varghese R; Shastri SS; Anantharaman D; Gheit T; Tommasino M; Sauvaget C; Pillai MR; Sankaranarayanan R
Lancet Oncol; 2021 Nov; 22(11):1518-1529. PubMed ID: 34634254
[TBL] [Abstract][Full Text] [Related]
11. Anogenital human papillomavirus virus DNA and sustained response to the quadrivalent HPV vaccine in women living with HIV-1.
Cespedes MS; Kang M; Kojic EM; Umbleja T; Godfrey C; Webster-Cyriaque JY; Masih R; Firnhaber C; Grinsztejn B; Saah A; Cu-Uvin S; Aberg JA
Papillomavirus Res; 2018 Dec; 6():15-21. PubMed ID: 30118852
[TBL] [Abstract][Full Text] [Related]
12. Decline in prevalence of human papillomavirus infection following vaccination among Australian Indigenous women, a population at higher risk of cervical cancer: The VIP-I study.
McGregor S; Saulo D; Brotherton JML; Liu B; Phillips S; Skinner SR; Luey M; Oliver L; Stewart M; Tabrizi SN; Garland S; Kaldor JM
Vaccine; 2018 Jul; 36(29):4311-4316. PubMed ID: 29880245
[TBL] [Abstract][Full Text] [Related]
13. Human papillomavirus prevalence and vaccine effectiveness in young women in Germany, 2017/2018: results from a nationwide study.
Loenenbach A; Schönfeld V; Takla A; Wiese-Posselt M; Marquis A; Thies S; Sand M; Kaufmann AM; Wichmann O; Harder T
Front Public Health; 2023; 11():1204101. PubMed ID: 37719724
[TBL] [Abstract][Full Text] [Related]
14. Incidence and Types of Human Papillomavirus Infections in Adolescent Girls and Young Women Immunized With the Human Papillomavirus Vaccine.
Schlecht NF; Diaz A; Nucci-Sack A; Shyhalla K; Shankar V; Guillot M; Hollman D; Strickler HD; Burk RD
JAMA Netw Open; 2021 Aug; 4(8):e2121893. PubMed ID: 34424304
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of human papillomavirus (HPV) types in cervical cancer 2003-2008 in Stockholm, Sweden, before public HPV vaccination.
Du J; Näsman A; Carlson JW; Ramqvist T; Dalianis T
Acta Oncol; 2011 Nov; 50(8):1215-9. PubMed ID: 21726177
[TBL] [Abstract][Full Text] [Related]
16. Follow-up on oral and cervical human papillomavirus prevalence 2013-2015 in youth at a youth clinic in Stockholm, Sweden.
Grün N; Ährlund-Richter A; Franzén J; Mirzaie L; Marions L; Ramqvist T; Dalianis T
Infect Dis (Lond); 2016 Feb; 48(2):169-70. PubMed ID: 26536907
[No Abstract] [Full Text] [Related]
17. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
[TBL] [Abstract][Full Text] [Related]
18. UK population based study to predict impact of HPV vaccination.
Hibbitts S; Tristram A; Beer H; McRea J; Rose B; Hauke A; Nuttall D; Dallimore N; Newcombe RG; Fiander A
J Clin Virol; 2014 Feb; 59(2):109-14. PubMed ID: 24388208
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction.
Chandler E; Ding L; Gorbach P; Franco EL; Brown DA; Widdice LE; Bernstein DI; Kahn JA
J Adolesc Health; 2018 Jul; 63(1):43-49. PubMed ID: 30060856
[TBL] [Abstract][Full Text] [Related]
20. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
